araag2/HINT huggingface dataset:
Clinical trial NCT00733005 (phase 3, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: mometasone furoate nasal spray (mfns), matching placebo nasal spray
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A subject must be 12 years of age or older, of either sex, and of any race.

          -  A subject must have at least a 2-year history of SAR which exacerbates during the
             study season.

          -  A subject must have a positive skin prick test response to an appropriate seasonal
             allergen at Visit 1.

          -  A subject must be clinically symptomatic at the Screening and Baseline Visits.

        Exclusion Criteria:

          -  A subject with a history of severe local reaction(s) or anaphylaxis to skin testing.

          -  A subject who has had an upper respiratory tract or sinus infection that required
             antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or
             who has had a viral upper respiratory infection within 7 days prior to the Screening
             Visit.

          -  A subject who has used any drug in an investigational protocol in the 30 days prior to
             the Screening Visit.

          -  A subject who is participating in any other clinical study.

          -  A subject who is part of the staff personnel directly involved with this study.

          -  A subject who is a family member (parent, spouse, or sibling) of the investigational
             study staff.

          -  A female subject who is breast-feeding, pregnant, or intends to become pregnant.

          -  A subject previously randomized into this study.

          -  A subject who has a family member (parent, spouse, or sibling) currently enrolled in
             this study.
Clinical trial NCT01323790 (phase 3, status: completed)
Conditions: opioid-induced constipation (oic)
ICD codes: F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: nktr-118, nktr-118, placebo
SMILES: COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5, COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent prior to any study-specific procedures.

          -  Self-reported active symptoms of OIC at screening (<3 SBMs/week and experiencing ≥1
             reported symptom of hard/lumpy stools, straining, or sensation of incomplete
             evacuation/anorectal obstruction in at least 25% of BMs over the previous 4 weeks);
             and Documented confirmed OIC (<3 SBMs/week on average over the 2-week OIC confirmation
             period.

          -  Receiving a stable maintenance opioid regimen consisting of a total daily dose of 30
             mg to 1000 mg of oral morphine, or equianalgesic amount(s) of 1 or more other opioid
             therapies for a minimum of 4 weeks prior to screening for non-cancer-related pain with
             no anticipated change in opioid dose requirement over the proposed study period as a
             result of disease progression.

          -  Willingness to stop all laxatives and other bowel regimens including prune juice and
             herbal products throughout the 2-week OIC confirmation period and the 12-week
             treatment period, and to use only bisacodyl as rescue medication if a BM has not
             occurred within at least 72 hours of the last recorded BM.

        Exclusion Criteria:

          -  Patients receiving Opioid regimen for treatment of pain related to cancer.

          -  History of cancer within 5 years from first study visit with the exception of basal
             cell cancer and squamous cell skin cancer.

          -  Medical conditions and treatments associated with diarrhea, intermittent loose stools,
             or constipation.

          -  Other issues to the gastrointestinal tract that could impose a risk to the patient.

          -  Pregnancy or lactation.
Clinical trial NCT00400725 (phase 3, status: completed)
Conditions: scalp psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: clobex shampoo 0.05%, clobex shampoo placebo
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects aged 18 years or older.

          -  Subjects with moderate to severe scalp psoriasis

        Exclusion Criteria:

          -  Subjects who need systemic treatment for their body psoriasis

          -  Subjects with a washout period for topical treatment(s) on the scalp less than:

               -  Corticosteroids 2 weeks

               -  All other anti-psoriasis medications 2 weeks

          -  Subjects with a washout period for systemic treatment(s) less than:

               -  PUVA therapy 4 weeks

               -  Biological therapies 12 weeks

               -  Treatments other than biologicals with a possible efficacy on psoriasis 4 weeks

               -  Treatment known to worsen psoriasis 2 weeks
Clinical trial NCT00623194 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin detemir, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed Consent obtained before any trial-related activities. (Trial-related
             activities are any procedure that would not have been performed during normal
             management of the subject). The parents or legal representative of the subject must
             sign and date the Informed Consent Form.

          -  Finalised 52 weeks of treatment with insulin detemir in trial NN304-1689.

          -  Fertile females (girls who have had their first menstrual period) must use adequate
             contraception (barrier methods, contraceptive pills or intrauterine device (IUD)) if
             there is any risk of pregnancy in the opinion of the Investigator. For Denmark and
             France only contraceptive pills or intrauterine device are considered as adequate
             contraceptive methods.

        Exclusion Criteria:

          -  Significant concomitant disease such as endocrine, hepatic, renal, cardiac,
             respiratory, neurological, gastrointestinal, malignant or pancreatic diseases as
             judged by the Investigator.

          -  Pregnant or the intention of becoming pregnant.

          -  Previous participation in this trial (defined as enrolment).
Clinical trial NCT01113047 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: aliskiren/amlodipine and aliskiren/amlodipine/hctz
SMILES: NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Essential hypertension stage II

          -  Male and female patients

          -  Age >= 18 years old

        Exclusion Criteria:

          -  Severe hypertension (systolic BP >= 180 mmHg, diastolic BP >= 110 mmHg

          -  Poorly controlled diabetes mellitus or type 1 DM

          -  History of myocardial infarction, stroke

          -  Presence of heart failure

          -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00451958 (phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: degarelix 80 mg / degarelix 80 mg, degarelix 160 mg / degarelix 160 mg, leuprolide 7.5 mg / degarelix 80 mg, leuprolide 7.5 mg / degarelix 160 mg
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Eligibility criteria:

        Inclusion/Exclusion Criteria:

          -  Patients with histologically proven prostate cancer of all stages in whom endocrine
             treatment is indicated.

          -  Signed informed consent

          -  The patients must have completed the FE 200486 CS21 Study.
Clinical trial NCT00218855 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: thalidomide, placebo
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with multiple myeloma in need of treatment

        Exclusion Criteria:

          -  Previous treatment against multiple myeloma

          -  Need of high dose chemotherapy with autologous stem cell support

          -  Women in fertile age

          -  Psychiatric disease or mental reduction leading to lack of cooperation

          -  Lack of consent

          -  Life expectancy below 3 months

          -  Active cancer of other etiology
Clinical trial NCT01581320 (phase 3, status: completed)
Conditions: postmenopausal women with osteoporosis
ICD codes: N95.0, N95.2
Drugs: test group, reference group
SMILES: CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female more than 40 years old in postmenopausal

        Exclusion Criteria:

          -  Subject who has a history of malignant cancer
Clinical trial NCT00086268 (phase 3, status: completed)
Conditions: non small cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: zoledronic acid, taxotere, carboplatin
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or Female patients at least of 18 years old

          -  Patients with diagnosed non-small cell lung cancer that cannot be treated by surgery

          -  Women must not be pregnant or attempting to become pregnant

          -  Able and willing to sign informed consent

        Exclusion Criteria:

          -  Patients with cancer that has spread to the bone

          -  Patients with cancer that has spread to the brain who are receiving treatment

          -  Patients with kidney disease

          -  Patients treated with other investigational drugs
Clinical trial NCT00524368 (phase 3, status: completed)
Conditions: human immunodeficiency virus - type 1
ICD codes: D84.9, D81.9, D83.9, D84.821, B20, D82.2, D84.822
Drugs: darunavir (drv), ritonavir (rtv)
SMILES: [H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with documented human immunodeficiency virus - Type 1 (HIV-1) infection

          -  Patients with a viral load greater than 1,000 HIV-1 ribonucleic acid (RNA) copies/mL

          -  Stable highly active antiretroviral therapy (HAART) regimen for at least 12 weeks at
             screening

          -  In the investigator's opinion, non-nucleoside reverse transcriptase inhibitors
             (NNRTIs) are not a valid treatment option, because of the patient's antiretroviral
             (ARV) treatment history, ARV resistance testing, medication-taking behavior, safety
             and tolerability concerns, or other patient-related factors

          -  Prescreening or/and screening plasma HIV-1 RNA greater than 1,000 copies/mL on HAART
             regimen at screening

        Exclusion Criteria:

          -  Presence of any currently active conditions that fit the definition of the World
             Health Organization (WHO) Clinical Stage 4, with the following exceptions: stable
             cutaneous kaposi's sarcoma (ie, no internal organ involvement other than oral lesions)
             that is unlikely to require any form of systemic therapy during the study time period,
             wasting syndrome

          -  Patients for whom an investigational ARV is part of the current regimen, with the
             following exceptions if applicable (depending on local regulatory approval):
             tenofovir, emtricitabine

          -  Previous or current use of enfuvirtide (ENF), tipranavir and/or DRV

          -  Life expectancy of less than 12 months

          -  Pregnant or breast-feeding females

          -  Any active clinically significant disease (eg, tuberculosis [TB], cardiac dysfunction,
             pancreatitis, acute viral infections) or findings during screening of medical history
             or physical examination that, in the investigator's opinion, would compromise the
             patient's safety or outcome of the study
Clinical trial NCT00385307 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: amibegron (sr58611a)
SMILES: CCOC(=O)COC1=CC=C2CC[C@@H](CC2=C1)NC[C@H](O)C1=CC=CC(Cl)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with Major Depressive Disorder diagnosed according to Diagnostic and
             Statistical Manual of Mental Disorders DSM-IV-TR

          -  Patient meets criteria for a recurrent Major Depressive Episode (MDE)

          -  Patient meets severity assessments of depression specified by the study

        Exclusion Criteria:

          -  Patient is at immediate risk for suicidal behavior

          -  Patient is with a unstable medical condition

          -  Patient with psychotic features, catatonic features, seasonal pattern or postpartum
             onset

          -  Patient has taken concomitant treatment that may interfere with valid collection or
             interpretation of study data

          -  Patient has been treated with non-pharmacologic therapy intended to treat depression
             in the past 6 months

          -  Patient has been treated with paroxetine (Paxil) within the previous 6 months

          -  Patient is pregnant or breastfeeding, or likely to become pregnant during the course
             of the study
Clinical trial NCT00065325 (phase 3, status: completed)
Conditions: locally advanced breast cancer, metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: fulvestrant, exemestane
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H], CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Biopsy confirmation of Breast Cancer

          -  Breast Cancer has continued to grow after having received treatment with an aromatase
             inhibitor

          -  Postmenopausal women defined as a women who has stopped having menstrual periods

          -  Evidence of hormone sensitivity

          -  Written informed consent to participate in the trial

        Exclusion Criteria:

          -  Previous treatment with Faslodex (fulvestrant) or Aromasin (exemestane)

          -  Any hormonal therapy used to modify the course of an additional medical condition
             after prior treatment with a non-steroidal aromatase inhibitor

          -  Treatment with an investigational or non-approved drug within one month

          -  An existing serious disease, illness, or condition that will prevent participation or
             compliance with study procedures

          -  A history of allergies to any active or inactive ingredients of Faslodex or Exemestane
             (i.e. castor oil or Mannitol)
Clinical trial NCT01369329 (phase 3, status: completed)
Conditions: crohn's disease, ibd, colitis, inflammatory bowel disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919, K52.3, K52.82, K52.831, K52.832, A06.2, K52.838, K52.839, M06.4, G61.89, G61.9, M35.81, G61.81, K75.9, M27.2
Drugs: group 2 ustekinumab 130 mg, group 3: ustekinumab approximately 6 mg/kg, group 1: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have Crohn's disease of at least 3 months' duration with colitis, ileitis, or
             ileocolitis, confirmed at some time in the past by radiography, histology, or
             endoscopy

          -  Have active Crohn's disease, defined as a baseline Crohn's Disease Activity Index
             (CDAI) score of >= 220 and <= 450

          -  Have received infliximab, adalimumab, or certolizumab pegol at a dose approved for the
             treatment of Crohn disease and did not respond initially (ie, primary nonresponse)

          -  Or responded initially but then lost response with continued therapy (ie, secondary
             nonresponse)

          -  Or were intolerant to the medication

          -  Have screening laboratory test results within protocol-specified parameters.

        Exclusion Criteria:

          -  Patients who have had any kind of bowel resection within 6 months

          -  Are pregnant or planning pregnancy (both men and women) while enrolled in the study or
             for 20 weeks after receiving study agent

          -  Patients who have received infliximab, adalimumab or certolizumab pegol < = 8 weeks
             before the first administration of study drug

          -  Patients with certain complications of Crohn's disease that would make it hard to
             assess response to study drug

          -  Patients with a history of or ongoing chronic or recurrent infectious disease

          -  Patients who have previously received a biologic agent targeting IL-12 or IL-23,
             including but not limited to ustekinumab (CNTO 1275) or briakinumab (ABT-874)
Clinical trial NCT00097916 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: memantine hcl
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Eligibility criteria:

        Inclusion Criteria:

          -  Moderate to Severe Alzheimer's Disease with a score greater than or equal to 4 on
             agitation/aggression domain of NPI

          -  Stable dose of donepezil for 3 months

        Exclusion Criteria:

          -  Other evidence of psychiatric disorders

          -  Oncologic diagnosis

          -  Clinically significant gastrointestinal, renal, hepatic, endocrine or cardiovascular
             disease
Clinical trial NCT01094886 (phase 3, status: completed)
Conditions: arthritis, osteoarthritis, knee, osteoarthritis, hip, thromboembolism
ICD codes: A01.04, A02.23, A39.83, A39.84, A54.42, B06.82, B26.85, M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30, M16.9, M16.0, M16.10, M16.11, M16.12, M16.30, M16.31, O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: rivaroxaban
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Undergone elective total hip or knee replacement surgery

          -  Received postoperative venous blood clot prevention therapy within 24 hours of the
             surgery

          -  Currently prescribed enoxaparin 30mg subcutaneous (SQ) twice a day or 40mg SQ daily
             for venous blood clotting prevention with an expected duration of continued prevention
             therapy of at least 3 days after admission to a subacute unit

          -  Discharged from the hospital to a subacute unit (including skilled nursing facilities
             and rehabilitation units) and committed to remaining in the unit for the duration of
             the Pharmacodynamic blood sampling period of the study

        Exclusion Criteria:

          -  Platelet count <90,000/µL based on screening laboratory assessments

          -  active internal bleeding or high risk of bleeding

          -  history of, or condition associated with, increased bleeding risk including

          -  planned invasive procedure with potential for uncontrolled bleeding, including major
             surgery

          -  sustained uncontrolled high blood pressure, defined as systolic blood pressure =180
             mmHg or diastolic blood pressure =100 mmHg

          -  clinically significant kidney disease and/or impaired kidney function

          -  clinically significant liver disease

          -  anemia

          -  known allergies, hypersensitivity, or intolerance to rivaroxaban

          -  indication for anticoagulant (blood thinning) therapy for a condition other than blood
             clot prevention

          -  anticipated need for treatment with a prescription or nonprescription non-steroidal
             anti-inflammatory drugs (NSAIDs)

          -  any patient who has taken more than one or two doses of aspirin (>100 mg/dose) in the
             week prior to enrollment will not be allowed to participate

          -  Drug addiction or alcohol abuse within 3 years prior to screening
Clinical trial NCT00504127 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 500 mg bid, placebo
SMILES: COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(=O)OCCCCO[N+]([O-])=O, COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(=O)OCCCCO[N+]([O-])=O, COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and Woman (40 or older) with a diagnosis of primary OA of the knee.

          -  Must be a current chronic user of NSAIDS or acetaminophen

          -  Must discontinue all analgesic therapy at Screening

        Exclusion Criteria:

          -  Uncontrolled Hypertension or Diabetes

          -  Hepatic or Renal Impairment

          -  Current or expected use of anti-coagulant

          -  Clinical relevant abnormal ECG

          -  A history of alcohol or drug abuse

          -  Candidates for imminent joint replacement

          -  Participation within 30 days prior to screening in another investigational study
Clinical trial NCT00729690 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: pregabalin, pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of osteoarthritis

          -  Subjects who can understand and communicate in English

        Exclusion Criteria:

          -  Younger than 55 years or older than 75 years.

          -  American Society of Anesthesiologists physical status IV

          -  Prior use of pregabalin or gabapentin will not be an exclusionary criterion; however
             patients will have been withdrawn from these medications at least 14 days before
             surgery

          -  Patients who are currently enrolled in another investigational study.